Becton Dickinson India Ltd, a 100
per cent subsidiary of the New Jersey-based Becton Dickinson, has commissioned a Rs-200
crore facility at Badwal (Haryana) for the manufacture of hypodermic medical devices. The
highly automated process plant has a capacity to make over a billion disposable needles a
The unit, which complies with current good manufacturing
practice (cGMP) requirements, will cater exclusively to the domestic market "thereby
ensuring regular supply at affordable prices," says C D Sharma, BDI''s managing
Becton Dickinson, the $3.2 billion Fortune 500 company,
has decided to invest a total of $100 million in India by 2000. Since launch in 1996, BDI
has invested $50 million in the core business area.
"We see a rapid growth in our Indian operations which
will offset the current meltdown in the South East Asia region," says BDC''s Asia
Pacific region president, Eugenio Naschold.
The Indian subsidiary has identified seven core business
areas for future investments. These include, besides injection systems, diabetes health
care, infusion therapy, sample collection, infectious diseases, diagnostics and pre-filled
syringes and immuno-cytometry systems.
The company is also concentrating on health care
management programmes and has recently designed a staged diabetes management (SDM) module
to improve the level of healthcare given to hypoglycaemics.
Becton Dickinson''s worldwide operations are spread over 80
locations in 40 countries. The company acquired $33-million research-oriented U.S. company
PharMingen in 1997 to broadbase its operations in monoclonal antibodies and reagents used
in research. The merger is expected to give the company a discovery-to-diagnostics
identity in the health and medicine field.